Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Adaptimmune Therapeutics (NASDAQ:ADAPGet Rating) from a sell rating to a hold rating in a report published on Monday, Zacks.com reports.

According to Zacks, “Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. “

A number of other research analysts have also recently weighed in on ADAP. SVB Leerink lowered their target price on shares of Adaptimmune Therapeutics from $7.00 to $3.00 and set a market perform rating on the stock in a research note on Tuesday, March 15th. StockNews.com began coverage on shares of Adaptimmune Therapeutics in a research note on Thursday, March 31st. They set a hold rating on the stock. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of Hold and an average target price of $6.92.

NASDAQ:ADAP opened at $1.42 on Monday. Adaptimmune Therapeutics has a 12 month low of $1.26 and a 12 month high of $6.86. The company has a 50 day simple moving average of $1.91 and a two-hundred day simple moving average of $2.99.

Adaptimmune Therapeutics (NASDAQ:ADAPGet Rating) last issued its quarterly earnings results on Monday, May 9th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.04). Adaptimmune Therapeutics had a negative return on equity of 76.84% and a negative net margin of 1,836.31%. During the same quarter in the previous year, the firm posted ($0.24) EPS. On average, sell-side analysts forecast that Adaptimmune Therapeutics will post -1.18 earnings per share for the current year.

A number of large investors have recently modified their holdings of the stock. BlackRock Inc. boosted its position in Adaptimmune Therapeutics by 28.5% in the 3rd quarter. BlackRock Inc. now owns 1,260,872 shares of the biotechnology company’s stock valued at $6,519,000 after buying an additional 279,478 shares during the period. Rock Springs Capital Management LP boosted its position in Adaptimmune Therapeutics by 41.7% in the 3rd quarter. Rock Springs Capital Management LP now owns 2,189,788 shares of the biotechnology company’s stock valued at $11,321,000 after buying an additional 644,788 shares during the period. Toroso Investments LLC purchased a new stake in Adaptimmune Therapeutics in the 3rd quarter valued at about $55,000. Balyasny Asset Management LLC purchased a new stake in Adaptimmune Therapeutics in the 3rd quarter valued at about $1,341,000. Finally, ACT Capital L.L.C. purchased a new stake in shares of Adaptimmune Therapeutics in the 3rd quarter worth approximately $465,000.

About Adaptimmune Therapeutics (Get Rating)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets.

Featured Stories

Get a free copy of the Zacks research report on Adaptimmune Therapeutics (ADAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.